Clinical Trial

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic). Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib, gemcitabine, and doxorubicin may work better in treating patients with kidney cancer.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-12
notable Primary completion moved earlier: 2027-01-31 -> 2026-08-04 2026-08-12
minor Completion moved earlier: 2027-01-31 -> 2026-08-04 2026-08-12
Trial Details
NCT Number NCT03587662
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Enrollment 30 participants
Start Date 2018-08-17
Primary Completion 2026-08-04 (estimated)
Study Completion 2026-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-11